Combination of | |
---|---|
Amlodipine | Calcium channel blocker |
Olmesartan | Angiotensin II antagonist |
Clinical data | |
Trade names | Azor, Sevikar |
Other names | Olmesartan/amlodipine |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Amlodipine/olmesartan, sold under the brand name Azor, among others is a fixed-dose combination medication used to treat high blood pressure.[5] It contains amlodipine, as the besilate, a dihydropyridine calcium channel blocker, and olmesartan medoxomil, an angiotensin II receptor blocker.[5]
Amlodipine/olmesartan was approved for medical use in the United States in September 2007.[5][7] It is available as a generic medication.
Medical uses
The combination is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.[5]
History
The combination has been studied in clinical trials; one test showed it reduced blood pressure during a 24-hour period and was well tolerated.[8]
References
- ^ "TGA eBS - Product and Consumer Medicine Information Licence". www.ebs.tga.gov.au.
- ^ "OLAMLO, OLMAKAR, OLMESARTAN/AMLODIPINE ASTRON, OLMESARTAN/AMLODIPINE INTAS (Accord Healthcare Pty Ltd)". Department of Health and Aged Age. Retrieved 3 April 2023.
- ^ "SEVIKAR 20/5 olmesartan medoxomil / amlodipine (as besilate) 20/5 mg tablet blister pack (157565)". Therapeutic Goods Administration (TGA). 27 May 2022. Retrieved 3 April 2023.
- ^ "Sevikar 20 mg/5 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 July 2022. Retrieved 19 March 2023.
- ^ a b c d e "Azor- amlodipine besylate and olmesartan medoxomil tablet, film coated". DailyMed. 7 September 2022. Retrieved 17 March 2023.
- ^ "Azor- amlodipine besylate and olmesartan medoxomil tablet, film coated". DailyMed. 7 June 2022. Retrieved 18 March 2023.
- ^ "Drug Approval Package: Azor (amlodipine and olmesartan medoxomil) NDA #022100". U.S. Food and Drug Administration (FDA). 17 December 2009. Retrieved 17 March 2023.
- ^ Alexander W (June 2009). "American society of hypertension and american urological association". P & T. 34 (6). Pharmacy & Therapeutics: 318–21. PMC 2697919. PMID 19572050.